Literatur
- 1
Hoaken P NS, Stewart S H.
Drugs of abuse and the elicitation of human aggressive behavior.
Addict Behav.
2003;
28
1533-1554
- 2
Söderpalm B, Ericson M, Olausson P. et al .
Nicotinic mechanisms involved in the dopamine activating and reinforcing properties
of ethanol.
Behav Brain Res.
2000;
113
85-96
- 3
Siggins G R, Martin G, Roberto M. et al .
Glutamatergic transmission in opiate and alcohol dependence.
Ann N Y Acad Sci.
2003;
1003
196-211
- 4
Kumar S, Fleming R L, Morrow A L.
Ethanol regulation of gamma-aminobutyric acid A receptors: genomic and nongenomic
mechanisms.
Pharmacol Ther.
2004;
101
211-226
- 5
Tupala E, Tiihonen J.
Dopamine and alcoholism: neurobiological basis of ethanol abuse.
Prog Neuropsychopharmacol Biol Psychiatry.
2004;
28
1221-1247
- 6
Alldredge B K, Lowenstein D H.
Status epilepticus related to alcohol abuse.
Epilepsia.
1993;
34
1033-1037
- 7
Neiman J, Haapaniemi H M, Hilborn M.
Neurological complications of drug abuse: pathophysiological mechanisms.
Eur J Neurol.
2000;
7
595-606
- 8
Martin P R, Singleton C K, Hiller-Sturmhöfel S.
The role of thiamine deficiency in alcoholic brain disease.
Alcohol Res Health.
2003;
27
134-142
- 9
Uchino A, Yuzuriha T, Murakami M. et al .
Magnetic resonance imaging of sequelae of central pontine myelinolysis in chronic
alcohol abusers.
Neuroradiology.
2003;
45
877-890
- 10
Kohler C G, Ances B M, Coleman A R. et al .
Marchiafava-Bignami disease: literature review and case report.
Neuropsychiatry Neuropsychol Behav Neurol.
2000;
13
67-76
- 11
Pahwa R, Lyons K E.
Essential tremor: differential diagnosis and current therapy.
Am J Med.
2003;
115
134-142
- 12
Pontieri F E, Passarelli F, Calò L, Caronti B.
Functional correlates of nicotine administration: similarity with drugs of abuse.
J Mol Med.
1998;
76
193-201
- 13
Picciotto M R.
Common aspects of the action of nicotine and other drugs of abuse.
Drug Alcohol Depend.
1998;
51
165-172
- 14
Mathieu-Kia A M, Kellogg S H, Butelman E R, Kreek M J.
Nicotine addiction: insights from recent animal studies.
Psychopharmacology.
2002;
162
102-118
- 15
Griffiths R R, Woodson P P.
Reinforcing properties of caffeine: studies in humans and laboratory animals.
Pharmacol Biochem Behav.
1998;
29
419-427
- 16
Daly J W, Fredholm B B.
Caffeine - an atypical drug of dependence.
Drug Alcohol Depend.
1998;
51
199-206
- 17
Nestler E J.
Historical review: molecular and cellular mechanisms of opiate and cocaine addiction.
Trends Pharmacol Sci.
2004;
25
210-218
- 18
Noda Y, Nabeshima T.
Opiate physical dependence and N-methyl-D-aspartate receptors.
Eur J Pharmacol.
2004;
500
121-128
- 19
Laviolette S R, Gallegos R A, Henriksen S I, Kooy D van der.
Opiate state controls bi-directional reward signaling via GABAAreceptors in the ventral tegemental area.
Nature Neurosci.
2004;
7
160-169
- 20
Zhang L C, Buccafusco J J.
Adaptive changes in M1 muscarinic receptors localized to sepcific rostral brain regions
during and after morphine withdrawal.
Neuropharmacology.
2000;
39
1720-1731
- 21
Bockstaele E J van, Menko A S, Drolet G.
Neuroadaptive responses in brainstem noradrenergic nuclei following chronic morphine
exposure.
Mol Neurobiol.
2001;
23
155-171
- 22
Brown C H, Russell J A.
Cellular mechanisms underlying neuronal excitability during morphine withdrawal in
physical dependence: lessons from the magnocellular oxytocin system.
Stress.
2004;
7
97-107
- 23
Zastrow M van, Svingos A, Haberstock-Debic H, Evans C.
Regulated endocytosis of opioid receptors: cellular mechanisms and proposed roles
in physiological adaptation to opioid drugs.
Curr Opin Neurobiol.
2003;
13
348-353
- 24
Ciccocioppo R, Angeletti S, Panocka I, Massi M.
Nociceptin/orphanin FQ and drugs of abuse.
Peptides.
2000;
21
1071-1080
- 25
Roumy M, Garnier M, Zajac J M.
Neuropeptide FF receptors 1 and 2 exert an anti-opioid activity in acutely dissociated
rat dorsal raphe and periventricular hypothalamic neurones.
Neurosci Lett.
2003;
348
159-162
- 26
Zachariou V, Thome J, Parikh K, Picciotto M R.
Upregulation of galanin binding sites and GalR1 mRNA levels in the mouse locus coeruleus
following chronic morphine treatments and precipitated morphine withdrawal.
Neuropsychopharmacology.
2000;
23
127-137
- 27
Bertran F, Denise P, Letellier P.
Nonconvulsive status epilepticus: the role of morphine and its antagonists.
Neurophysiol Clin.
2000;
30
109-112
- 28
Breivink H.
Opioids in cancer and chronic non-cancer pain therapy - indications and controversies.
Acta Anaesthesiol Scand.
2001;
45
1059-1066
- 29
Sporer K A.
Acute heroin overdose.
Ann Intern Med.
1999;
130
584-590
- 30
Alldredge B K, Lowenstein D H, Simon R P.
Seizures associated with recreational drug abuse.
Neurology.
1989;
39
1037-1039
- 31
Andersen S N, Skullerud K.
Hypoxic/brain ischemia damage, especially pallidal lesions, in heroin addicts.
Forensic Sci Int.
1999;
102
51-59
- 32
Stamboulis E, Psimaras A, Malliara-loulakaki S.
Brachial and lumbar plexitis as a reaction to heroin.
Drug Alcohol Depend.
1988;
22
205-207
- 33
Bernasconi A, Kuntzer T, Ladbon N. et al .
Complications neurologiques périphériques et médullaires de la toxicomanie intraveineuse
à l'héroine.
Rev Neurol.
1996;
152
688-694
- 34
Friedman H, Eisenstein T K.
Neurological basis of drug dependence and its effects on the immune system.
J Neuroimmunol.
2004;
147
106-108
- 35
Vallejo R, Leon-Casasola O de, Ramsun B.
Opioid therapy and immunosuppression: a review.
Am J Ther.
2004;
11
354-365
- 36
Long H, Deore K, Hoffman R S, Nelson L S.
A fatal case of spongiform leukoencephalopathy linked to „chasing the dragon”.
J Toxicol Clin Toxicol.
2003;
41
887-891
- 37
Wilson S J, Sayette M A, Fiez J A.
Prefrontal responses to drug cues: a neurocognitive analysis.
Nature Neurosci.
2004;
7
211-214
- 38
Rogers R D, Robbins T W.
Investigating the neurocognitive deficits associated with chronic drug misuse.
Curr Opin Neurobiol.
2001;
11
250-257
- 39
Cicero T J, Inciardi J A.
Diversion and abuse of methadone prescribed for pain management.
JAMA.
2005;
293
297-298
- 40
Manfredi P L, Gonzales G R, Payne R.
Reversible spastic paraparesis induced by high-dose intravenous metadone.
J Pain.
2001;
2
77-79
- 41
Amara S G, Sonders M S.
Neurotransmitter transporters as molecular targets for addictive drugs.
Drug Alcohol Depend.
1998;
51
87-96
- 42
Rothman R B, Baumann M H.
Monoamine transporters and psychostimulant drugs.
Eur J Pharmacol.
2003;
479
23-40
- 43
Homberg J R, Raaso H S, Schoffelmeer A NM, Vries T J de.
Individual differences in sensitivity to factors provoking reinstatement of cocaine-seeking
behavior.
Behav Brain Res.
2004;
152
157-161
- 44
Kalivas P W.
Glutamate systems in cocaine addiction.
Curr Opin Pharmacol.
2004;
4
23-29
- 45
Heinemann A, Miyashi S, Iwersen S. et al .
Body-packing as a cause of unexpected sudden death.
Forensic Sci Int.
1998;
92
1-10
- 46
Lowenstein D H, Massa S M, Rowbotham M C. et al .
Acute neurologic and psychiatric complications associated with cocaine abuse.
Am J Med.
1987;
83
841-846
- 47
Ye J H, Liu P L, Wu W H, McArdle J J.
Cocaine depresses GABAA current of hippocampal neurons.
Brain Res.
1997;
770
169-175
- 48
Gasior M, Ungard J T, Witkin J M.
Preclinical evaluation of newly approved and potential antiepileptic drugs against
cocaine-induced seizures.
J Pharmacol Exp Ther.
1999;
290
1148-1156
- 49
Witkin J M, Gasior M, Heifets B, Tortella F C.
Anticonvulsant efficacy of N-methyl-D-aspartate antagonists against convulsions induced
by cocaine.
J Pharmacol Exp Ther.
1999;
289
703-711
- 50
Gasior M, Kaminski R, Witkin J M.
Pharmacological modulation of GABAB receptors affects cocaine-induced seizures in mice.
Psychopharmacology.
2004;
174
211-219
- 51
Johnson B A, Devous M D, Ruiz P, Ait-Daoud N.
Treatment advances for cocaine-induced ischemic stroke: focus on dihydropyridine-class
calcium channel antagonists.
Am J Psychiatry.
2001;
158
1191-1198
- 52
Fessler R D, Esshaki C M, Stankewitz R C. et al .
The neurovascular complications of cocaine.
Surg Neurol.
1997;
47
339-345
- 53
Merkel P A, Koroshetz W J, Irizarry M C, Cudkowicz M E.
Cocaine-associated cerebral vasculitis.
Semin Arthritis Rheum.
1995;
25
172-183
- 54
Aggarwal S K, Williams V, Levine S R. et al .
Cocaine-associated intracranial hemorrhage: absence of vasculitis in 14 cases.
Neurology.
1996;
46
1741-1743
- 55
Bartzokis G, Beckson M, Lu P H. et al .
Age-related brain volume reductions in amphetamine and cocaine addicts and normal
controls: implications for addiction research.
Psychiatry Res.
2000;
98
93-102
- 56
Büttner A, Mall G, Penning R. et al .
The neuropathology of cocaine abuse.
Legal Med.
2003;
5
S240-S242
- 57
Cardoso F, Jankovic J.
Movement disorders.
Neurol Clin.
1993;
11
625-638
- 58
Daras M, Koppel B S, Atos-Radzion E.
Cocaine-induced choreoathetoid movements („crack dancing”).
Neurology.
1994;
44
751-752
- 59
Cardoso F, Jankovic J.
Cocaine-related movement disorders.
Mov Disord.
1993;
8
175-178
- 60
Richards J R.
Rhabdomyolysis and drugs of abuse.
J Emerg Med.
2000;
19
51-56
- 61
Martinsson L, Wahlgren N G.
Safety of Dexamphetamine in acute ischemic stroke. A randomized, double-blind, controlled
dose-escalation trial.
Stroke.
2003;
34
475-481
- 62
White F J, Kalivas P W.
Neuroadaptations involved in amphetamine and cocaine addiction.
Drug Alcohol Depend.
1998;
51
141-153
- 63
Zagoni P G, Albano C.
Psychostimulants and epilepsy.
Epilepsia.
2002;
43 (Suppl 2)
S28-S31
- 64
Selmi F, Davies K G, Sharma R R, Neal J W.
Intracerebral haemorrhage due to amphetamine abuse: report of two cases with underlying
arteriovenous malformations.
Br J Neurosurg.
1995;
9
93-96
- 65
Buxton N, McConachie N S.
Amphetamine abuse and intracranial haemorrhage.
J R Soc Med.
2000;
93
472-477
- 66
Schiorring E.
Psychopathology induced by „speed drugs”.
Pharmacol Biochem Behav.
1981;
14 (Suppl 1)
S109-S122
- 67
Hanson G R, Rau K S, Fleckenstein A E.
The methamphetamine experience: a NIDA partnership.
Neuropharmacology.
2004;
47
92-100
- 68
Davidson C, Gow A J, Lee T H, Ellinwood E H.
Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to
human abuse and treatment.
Brain Res Rev.
2001;
36
1-22
- 69
Cadet J L, Jayanthi S, Deng X.
Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal
degeneration and neuronal apoptosis.
FASEB J.
2003;
17
1775-1788
- 70
Perez Jr J A, Arsura E L, Strategos S.
Methamphetamine-related stroke: four cases.
J Emerg Med.
1999;
17
469-471
- 71
Wijaya J, Salu P, Leblanc A, Bervoets S.
Acute unilateral visual loss due to a single intranasal methamphetamine abuse.
Bull Soc Belge Ophtalmol.
1999;
271
19-25
- 72
Guilarte T R.
Is methamphetamine abuse a risk factor in parkinsonism?.
Neurotoxicology.
2001;
22
725-731
- 73
Moszczynska A, Fitzmaurice P, Ang L. et al .
Why is parkinsonism not a feature of human methamphetamine users?.
Brain.
2004;
127
363-370
- 74
Nordahl T E, Salo R, Leamon M.
Neuropsychological effects of chronic methamphetamine use on neurotransmitters and
cognition: a review.
J Neuropsychiatry Clin Neurosci.
2003;
15
317-325
- 75
Newton T F, Cook I A, Kalechstein A D. et al .
Quantitative EEG abnormalities in recently abstinent methamphetamine dependent individuals.
Clin Neurophysiol.
2003;
114
410-415
- 76
Nath A, Maragos W F, Avison M J. et al .
Acceleration of HIV dementia with methamphetamine and cocaine.
J Neurovirol.
2001;
7
66-71
- 77
Urbina A, Jones K.
Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric
aspects of a new epidemic.
Clin Infect Dis.
2004;
38
890-894
- 78
Weir E.
Raves: a review of the culture, the drugs and the prevention of harm.
CMAJ.
2000;
162
1843-1848
- 79
Green A R, Mechan A O, Elliott J M. et al .
The pharmacology and clinical pharmacology of 3,4-methylendioxymethamphetamine (MDMA,
„Ecstasy”).
Pharmacol Rev.
2003;
55
463-508
- 80
Kalant H.
The pharmacology and toxicology of „ecstasy” (MDMA) and related drugs.
CMAJ.
2001;
165
917-928
- 81
Gahlinger P M.
Club drugs: MDMA gamma-hydroxybutyrate (GHB), rohypnol, and ketamine.
Am Fam Phys.
2004;
69
2619-2627
- 82
Jansen K LR.
Ecstasy (MDMA) dependence.
Drug Alcohol Depend.
1999;
53
121-124
- 83
Boyer E W, Shannon M.
The serotonin syndrome.
New Engl J Med.
2005;
352
1112-1120
- 84
Green A R, O'Shea E, Colado M I.
A review or the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic
response.
Eur J Pharmacol.
2004;
500
3-13
- 85
Henry J A, Jeffreys K J, Dawling S.
Toxicity and deaths from 3,4-methylendioxymethamphetamine („ecstasy”).
Lancet.
1992;
340
384-387
- 86
Holmes S B, Banerjee A K, Alexander W D.
Hyponatraemia and seizures after ecstasy use.
Postgrad Med J.
1999;
75
32-34
- 87
Burgess C, O'Donohoe A, Gill M.
Agony and ecstasy: a review of MDMA effects and toxicity.
Eur Psychiatry.
2000;
15
287-294
- 88
Hartung T K, Schofield E, Short A I. et al .
Hyponatraemic states following 3,4-methylendioxymethamphetamine (MDMA, „Ecstasy”)
ingestion.
Q J Med.
2002;
95
431-437
- 89
Ben-Abraham R, Szold O, Rudick V, Weinbroum A A.
„Ecstasy” intoxication: life-threatening manifestations and resuscitative measures
in the intensive care setting.
Eur J Emerg Med.
2003;
10
309-313
- 90
McEvoy A W, Kitchen N D, Thomas D G.
Intracerebral haemorrhage and drug abuse in young adults.
Br J Neurosurg.
2000;
14
449-454
- 91
Auer J, Berent R, Weber T. et al .
Subarachnoid haemorrhage with „Ecstasy” abuse in a young adult.
Neurol Sci.
2002;
23
199-201
- 92
Turner J JD, Parott A C.
„Is MDMA a human neurotoxin?”: Diverse views from the discussants.
Neuropsychobiology.
2000;
42
42-48
- 93
Ricaurte G A, Yuan J, Hatzidimitrou G. et al .
Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen
of MDMA („Ecstasy”).
Science.
2002;
297
2260-2263
, Retraction: Science 2003; 301: 1479
- 94
Lyles J, Cadet J L.
Methylendioxymethamphetamine (MDMA, Ecstasy) neurotoxicity: cellular and molecular
mechanisms.
Brain Res Rev.
2003;
42
155-168
- 95
Halpern J H, Pope Jr H G, Sherwood A R. et al .
Residual neuropsychological effects of illicit 3,4-methylendioxymethamphetamine (MDMA)
in individuals with minimal exposure to other drugs.
Drug Alcohol Depend.
2004;
75
135-147
- 96
Lyvers M, Hasking P.
Have Halpern et al. (2004) detected „residual neuropsychological effects” of MDMA?
Not likely.
Drug Alcohol Depend.
2004;
75
149-152
- 97
Sprague J E, Everman S L, Nichols D E.
An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylendioxymethamphetamine.
Neurotoxicology.
1998;
19
427-441
- 98
McCardle K, Luebbers S, Carter J D. et al .
Chronic MDMA (ecstasy) use, cognition and mood.
Psychopharmacology.
2004;
173
434-439
- 99
Freese T E, Miotto K, Reback C J.
The effects and consequences of selected club drugs.
J Subst Abuse Treat.
2002;
23
151-156
- 100
Cole J C, Sumnall H R.
Altered states: the clinical effects of ecstasy.
Pharmacol Ther.
2003;
98
35-58
- 101
Vecellio M, Schopper C, Modestin J.
Neuropsychiatric consequences (atypical psychosis and complex-partial seizures) of
ecstasy use: possibile evidence for toxicity-vulnerability predictors and implications
for preventive and clinical care.
J Psychopharmacol.
2003;
17
342-345
- 102
Kish S J.
What is the evidence that ecstasy (MDMA) can cause Parkinson's disease?.
Mov Disord.
2003;
18
1219-1223
- 103
Refstad S.
Paramethoxyamphetamine (PMA) poisoning: a „party drug” with lethal effect.
Acta Anaesthesiol Scand.
2003;
47
1298-1299
- 104
Gschwandtner U, Aston J, Renaud S, Fuhr P.
Pathologic gambling in patients with Parkinson's disease.
Clin Neuropharmacol.
2001;
24
170-172
- 105
Lawrence A D, Evans A H, Lees A J.
Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems
gone awry?.
Lancet Neurol.
2003;
2
595-604
- 106
Dodd M L, Klos K J, Bower J H. et al .
Pathologic gambling caused by drugs used to treat Parkinson disease.
Arch Neurol.
2005;
62
1301-1305
- 107
Allison C, Pratt J A.
Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence.
Pharmacol Ther.
2003;
98
171-195
- 108
Gatzonis S D, Angelopoulos E KD, Askalopoulou E G. et al .
Convulsive status epilepticus following abrupt high-dose benzodiazepine discontinuation.
Drug Alcohol Depend.
2000;
59
95-97
- 109
Olnes M J, Golding A, Kaplan P W.
Nonconvulsive status epilepticus resulting from benzodiazepine withdrawal.
Ann Intern Med.
2003;
139
956-958
- 110
Thomas P, Lebrun C, Chatel M.
De novo absence status epilepticus as a benzodiazepine withdrawal syndrome.
Epilepsia.
1993;
34
355-358
- 111
Druid H, Holmgren P, Ahlner J.
Flunitrazepam: an evaluation of use, abuse, and toxicity.
Forensic Sci Int.
2001;
122
136-141
- 112
Nicholson K L, Balster R L.
GHB: a new and novel drug of abuse.
Drug Alcohol Depend.
2001;
63
1-22
- 113
Wong C GT, Gibson K M, Snead 3rd
O C.
From the street to the brain: neurobiology of the recreational drug γ-hydroxybutyric
acid.
Trends Pharmacol Sci.
2004;
25
29-34
- 114
Wong C G, Chan K F, Gibson K M, Snead 3rd
O C.
Gamma-hydroxybutyric acid: neurobiology and toxicology of a recreational drug.
Toxicol Rev.
2004;
23
3-20
- 115
Snead 3rd
O C, Gibson K M.
γ-hydroxybutyric acid.
New Engl J Med.
2005;
352
2721-2732
- 116
Wong C GT, Bottiglieri T, Snead 3rd
O C.
GABA, γ-hydroxybutyric acid, and neurological disease.
Ann Neurol.
2003;
54 (Suppl 6)
S3-S12
- 117
Li J, Stokes S A, Woeckener A.
A tale of novel intoxication: seven cases of γ-hydroxybutyric acid overdose.
Ann Emerg Med.
1998;
31
723-728
- 118
Dyer J E.
γ-Hydroxybutyrate: a health-food product producing coma and seizure-like activity.
Am J Emerg Med.
1991;
9
321-324
- 119
Chin M Y, Dyer J E.
Acute poisoning from γ-hydroxybutyrate in California.
West J Med.
1992;
156
380-384
- 120
Li J, Stokes S A, Woeckener A.
A tale of novel intoxication: A review of the effects of γ-hydroxybutyric acid with
recommendations for management.
Ann Emerg Med.
1998;
31
729-736
- 121
Degenhardt L, Darke S, Dillon P.
The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian
users.
Addiction.
2003;
98
199-204
- 122
Kam P CA, Yoong F FY.
Gamma-hydroxybutyric acid: an emerging recreational drug.
Anaesthesia.
1998;
53
1195-1198
- 123
Schwartz R H, Milteer R, LeBeau M A.
Drug-facilitated sexual assault (date rape).
Southern Med J.
2000;
93
558-561
- 124
Novak S J.
Second thoughts on psychedelic drugs.
Endeavour.
1998;
22
21-23
- 125
Marek G J, Aghajanian G K.
Indoleamine and the phenethylamine hallucinogens: mechanisms of psychomimetic action.
Drug Alcohol Depend.
1998;
51
189-198
- 126
Nichols D E.
Hallucinogens.
Pharmacol Ther.
2004;
101
131-181
- 127
Supprian T, Frey U, Supprian R. et al .
Über den Gebrauch psychoaktiver Pilze als Rauschmittel.
Fortschr Neurol Psychiat.
2001;
69
597-602
- 128
Halpern J H.
Hallucinogens and dissociative agents naturally growing in the United States.
Pharmacol Ther.
2004;
102
131-138
- 129
Aghajanian G K, Marek G J.
Serotonin and hallucinogens.
Neuropsychopharmacology.
1999;
21 (Suppl 2)
S16-S23
- 130
Halpern J H, Pope Jr H G.
Hallucinogen persisting perception disorder: what do we know after 50 years?.
Drug Alcohol Depend.
2003;
69
109-119
- 131
Mangini M.
Treatment of alcoholism using psychedelic drugs: a review of the program of research.
J Psychoactive Drugs.
1998;
30
381-418
- 132
Halpern J H.
Hallucinogens: an update.
Curr Psychiatry Rep.
2003;
5
347-354
- 133
Delgado P L, Moreno F A.
Hallucinogens, serotonin and obsessive-compulsive disorder.
J Psychoactive Drugs.
1998;
30
359-366
- 134
Farlow M R.
NMDA receptor antagonists. A new therapeutic approach for Alzheimer's disease.
Geriatrics.
2004;
59
22-27
- 135
Thanvi B R, Lo T C.
Long-term motor complications of levodopa: clinical features, mechanisms, and management
strategies.
Postgrad Med J.
2004;
80
452-458
- 136
Lindahl J S, Keifer J.
Glutamate receptor subunits are altered in forebrain and cerebellum in rats chronically
exposed to the NMDA receptor antagonist phencyclidine.
Neuropsychopharmacology.
2004;
29
2065-2073
- 137
Jentsch J D, Roth R H.
The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the
dopamine hypothesis of schizophrenia.
Neuropsychopharmacology.
1999;
20
201-225
- 138
Pestaner J P, Southall P E.
Sudden death during arrest and phencyclidine intoxication.
Am J Forensic Med Pathol.
2003;
24
119-122
- 139
Thaker G K, Carpenter Jr W T.
Advances in schizophrenia.
Nat Med.
2001;
6
667-671
- 140
Murray J B.
Phencyclidine (PCP): a dangerous drug, but useful in schizophrenia research.
J Psychol.
2002;
136
319-327
- 141
McCarron M M, Schulze B W, Thompson G A. et al .
Acute phencyclidine intoxication: incidence of clinical findings in 1000 cases.
Ann Emerg Med.
1981;
10
237-242
- 142
Reich D L, Silvay G.
Ketamine: an update on the first twenty-five years of clinical experience.
Can J Anaesth.
1989;
36
186-197
- 143
Petrenko A B, Yamakura T, Fujiwara N. et al .
Reduced sensitivity to ketamine and pentobarbital in mice lacking the N-methyl-D-aspartate
receptor GluRε1 subunit.
Anesth Analg.
2004;
99
1136-1140
- 144
Vry J De, Jentzsch K R.
Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine.
Behav Pharmacol.
2003;
14
229-235
- 145
Jansen K L, Darracot-Cankovic R.
The nonmedical use of ketamine, part two: a review of problem use and dependence.
J Psychoactive Drugs.
2001;
33
151-158
- 146
Balster R L.
Neural basis of inhalant abuse.
Drug Alcohol Depend.
1998;
51
207-214
- 147
Zimmermann M.
Pathobiology of neuropathic pain.
Eur J Pharmacol.
2001;
429
23-37
- 148
Fujinaga M, Maze M.
Neurobiology of nitrous oxide-induced antinociceptive effects.
Mol Neurobiol.
2002;
25
167-189
- 149
Aydin K, Sencer S, Ogel K. et al .
Single-voxel proton MR spectroscopy in toluene abuse.
Magn Reson Imaging.
2003;
21
777-785
- 150
Filley C M, Halliday W, Kleinschmidt-DeMasters B K.
The effects of toluene on the central nervous system.
J Neuropathol Exp Neurol.
2004;
63
1-12
- 151
Anderson C E, Loomis G A.
Recognition and prevention of inhalant abuse.
Am Fam Physician.
2003;
68
869-874
- 152
Childers S R, Breivogel C S.
Cannabis and endogenous cannabinoid systems.
Drug Alcohol Depend.
1998;
51
173-187
- 153
Ameri A.
The effects of cannabinoids on the brain.
Prog Neurobiol.
1999;
58
315-348
- 154
Devane W A, Dysarz 3rd
F A, Johnson M R. et al .
Determination and characterization of a cannabinoid receptor in rat brain.
Mol Pharmacol.
1988;
34
605-613
- 155
Matsuda L A, Lolait S J, Brownstein M J. et al .
Structure of a cannabinoid receptor and functional expression of cloned DNA (cDNA).
Nature.
1990;
346
561-564
- 156
Devane W A, Hanus L, Breuer A. et al .
Isolation and structure of a brain constituant that binds to the cannabinoid receptor.
Science.
1992;
258
1946-1949
- 157
Fride E.
Endocannabinoids in the central nervous system - an overview.
Prostagl Leukotr Essent Fatty Acids.
2002;
66
221-233
- 158
Baker D, Pryce G, Giovannoni G, Thompson A J.
The therapeutic potential of cannabis.
Lancet Neurol.
2003;
2
291-298
- 159
Howlett A C, Breivogel C S, Childers S R. et al .
Cannabinoid physiology and pharmacology: 30 years of progress.
Neuropharmacology.
2004;
47
345-358
- 160
Ashton C H.
Pharmacology and effects of cannabis: a brief overview.
Br J Psychiatry.
2001;
178
101-106
- 161
Iversen L.
Cannabis and the brain.
Brain.
2003;
126
1252-1270
- 162
Moussouttas M.
Cannabis use and cerebrovascular disease.
Neurologist.
2004;
10
47-53
- 163
Mateo I, Pinedo A, Gomez-Beldarrain M. et al .
Recurrent stroke associated with cannabis use.
J Neurol Neurosurg Psychiatry.
2005;
76
435-437
- 164
Tanda G, Goldberg S R.
Cannabinoids: reward, dependence, and underlying neurochemical mechanisms - a review
of recent preclinical data.
Psychopharmacology.
2003;
169
115-134
- 165
Macleod J, Oakes R, Copello A. et al .
Psychological and social sequelae of cannabis and other illicit drug use by young
people: a systemic review of longitudinal, general population studies.
Lancet.
2004;
363
1579-1588
- 166
Lane S D, Cherek D R, Tcheremissine O V. et al .
Acute marijuana effects on human risk taking.
Neuropsychopharmacology.
2005;
30
800-809
- 167
Veen N D, Selten J P, Tewel I van der. et al .
Cannabis use and age at onset of schizophrenia.
Am J Psychiatry.
2004;
161
501-506
- 168
Drewe M, Drewe J, Riecher-Rössler A.
Cannabis and risk of psychosis.
Swiss Med Wkly.
2004;
134
659-663
- 169
Henquet C, Krabbendam L, Spauwen J. et al .
Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic
symptoms in young people.
BMJ.
2005;
330
11
, doi:
DOI: 10.1136/bmj.38267.664086.63
, (published 1 December 2004)
- 170
Favrat B, Menetrey A, Augsburger M. et al .
Two cases of „cannabis acute psychosis” following the administration of oral cannabis.
BMC Psychiatry.
2005;
5
17
, doi:
DOI: 10.1186/1471-244X-5-17
- 171
Ralevic V.
Cannabinoid modulation of peripheral autonomic and sensory neurotransmission.
Eur J Pharmacol.
2003;
472
1-21
- 172
Zajicek J, Fox P, Sanders H. et al .
Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis
(CAMS study): multicentre randomised placebo-controlled trial.
Lancet.
2003;
362
1517-1526
- 173
Gorter R W, Butorac M, Cobian E P, Sluis W van der.
Medical use of cannabis in the Netherlands.
Neurology.
2005;
64
917-919
- 174
Chen K, Ratzliff A, Hilgenberg L. et al .
Long-term plasticity of endocannabinoid-signaling induced by developmental febrile
seizures.
Neuron.
2003;
39
599-611
- 175
Wallace M J, Blair R E, Falenski K W. et al .
The endogenous cannabinoid system regulates seizure frequency and duration in a model
of temporal lobe epilepsy.
J Pharmacol Exp Ther.
2003;
307
129-137
- 176
Panikashvili D, Simeonidou C, Ben-Shabat S. et al .
An endogenous cannabinoid (2-AG) is neuroprotective after brain injury.
Nature.
2001;
413
527-531
- 177
Pryce G, Ahmed Z, Hankey D JR. et al .
Cannabinoids inhibit neurodegeneration in models of multiple sclerosis.
Brain.
2003;
126
2191-2202
- 178
Black S C.
Cannabinoid receptor antagonists and obesity.
Curr Opin Investig Drugs.
2004;
5
389-394
- 179
Fernandez J R, Allison D B.
Rimonabant Sanofi-Synthélabo.
Curr Opin Invest Drugs.
2004;
5
430-435
Dr. med. Stephan Rüegg
Abt. f. klinische Neurophysiologie · Neurologische Klinik · Universitätsspital
Petersgraben 4
4031 Basel · Schweiz
eMail: srueegg@uhbs.ch
